---
title: "Neuren Pharmaceuticals Outlines Procedures for Virtual Shareholder Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283929482.md"
description: "Neuren Pharmaceuticals Limited has issued an online meeting guide for its upcoming virtual shareholder meeting, detailing technical requirements and registration processes for shareholders and proxies. The guide aims to facilitate remote participation in governance. The latest analyst rating for Neuren Pharmaceuticals (AU:NEU) is a Buy, with a price target of A$19.10. The company focuses on developing therapeutics and has a market cap of A$1.57B."
datetime: "2026-04-24T03:38:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283929482.md)
  - [en](https://longbridge.com/en/news/283929482.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283929482.md)
generator: "portal-rs"
---

# Neuren Pharmaceuticals Outlines Procedures for Virtual Shareholder Meeting

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an update.

Neuren Pharmaceuticals has issued an online meeting guide for shareholders and appointed proxies ahead of an upcoming virtual shareholder meeting. The guide details technical requirements, including supported browsers and necessary identification such as shareholder or proxy numbers, and explains how investors can register, access the live webcast, view presentation slides, obtain electronic voting cards, and submit full or partial votes on meeting resolutions, underscoring the company’s move to streamline and formalize remote participation in its governance processes.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$19.10 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

**More about Neuren Pharmaceuticals Limited**

Neuren Pharmaceuticals Limited is a biotechnology company focused on developing therapeutics, with its shares held by individual and institutional investors who participate in corporate governance through shareholder meetings and proxy voting.

**Average Trading Volume:** 540,264

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$1.57B

Learn more about NEU stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [NEU.AU](https://longbridge.com/en/quote/NEU.AU.md)

## Related News & Research

- [Bell Potter Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)](https://longbridge.com/en/news/297151708.md)
- [Neuren Pharmaceuticals (ASX:NEU) Wins CHMP Backing, Is The Upside Already Priced In?](https://longbridge.com/en/news/291514830.md)
- [Macquarie Keeps Their Hold Rating on Region Group (SCPAF)](https://longbridge.com/en/news/298185411.md)
- [US watchdog to conduct review of whistleblower warning on mail-in voting rules](https://longbridge.com/en/news/298355308.md)
- [Simon Henry Spends AU$97k On DGL Group Stock](https://longbridge.com/en/news/298361741.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**